NattoPharma proudly announces that article 13.1 health claims for MenaQ7 are now available for bone and for cardiovascular health.

 

As part of our regulatory strategy NattoPharma filed in October 2007 health claims for MenaQ7 according to article 13.1 in the new Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods.

 

The filing was done through The Netherlands as the EU Member State on behalf of NattoPharma, and filings for both bone and cardiovascular health were conducted.  The Dutch "Ministerie van Volksgezondheis, Welzijn en Sport (Ministry of Health Welfare and Sport)" has further submitted the following article 13.1 health claims to the European Commission:

 

 

 

 

"MK-7 is a highly bioavailable form of vitamin K that helps maintain a healthy

  cardiovascular system"

 

 

"MK-7 is a highly bioavailable form of vitamin K that helps keep the heart and blood vessels healthy"

 

The claims can be found on the list "Other substances" ref:

http://www.row.minvws.nl/content.aspx?cid=176 . Please see substance no NL E109-0-1 and NLE109-E-2.

 

The health claims can be used for marketing purposes, and preferentially marked "Submitted to the European Commission under Regulation (EC) No 1924/2006, article 13.1".

 

To further substantiate the health claims, NattoPharma has made dossiers for both bone and cardiovascular claims.